JPWO2020109864A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020109864A5 JPWO2020109864A5 JP2021530885A JP2021530885A JPWO2020109864A5 JP WO2020109864 A5 JPWO2020109864 A5 JP WO2020109864A5 JP 2021530885 A JP2021530885 A JP 2021530885A JP 2021530885 A JP2021530885 A JP 2021530885A JP WO2020109864 A5 JPWO2020109864 A5 JP WO2020109864A5
- Authority
- JP
- Japan
- Prior art keywords
- isolated
- peptide
- seq
- dpep
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101700032448 DPEP1 Proteins 0.000 claims description 20
- 150000001413 amino acids Chemical class 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 206010063837 Reperfusion injury Diseases 0.000 claims description 8
- 238000006640 acetylation reaction Methods 0.000 claims description 6
- 230000004048 modification Effects 0.000 claims description 5
- 238000006011 modification reaction Methods 0.000 claims description 5
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 4
- 150000008574 D-amino acids Chemical class 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 206010022114 Injury Diseases 0.000 claims description 4
- 206010027476 Metastasis Diseases 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 206010038436 Renal failure acute Diseases 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- 238000007112 amidation reaction Methods 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 230000011987 methylation Effects 0.000 claims description 4
- 238000007069 methylation reaction Methods 0.000 claims description 4
- 210000000056 organs Anatomy 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 238000002054 transplantation Methods 0.000 claims description 4
- 125000000539 amino acid group Chemical group 0.000 claims description 2
- 238000007413 biotinylation Methods 0.000 claims description 2
- 125000003636 chemical group Chemical group 0.000 claims description 2
- 230000003899 glycosylation Effects 0.000 claims description 2
- 238000006206 glycosylation reaction Methods 0.000 claims description 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 2
- 238000007363 ring formation reaction Methods 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
Description
種々の変化および改変が、本発明から逸脱することなしにどのようになされ得るかは、理解されるであろう。
本発明は、例えば以下の項目を提供する。
(項目１)
（ａ）ＬＳＡＬＴを含むアミノ酸配列および（ｂ）Ｎ末端に、少なくとも１つの追加のグリシン残基を含む単離されたＤＰＥＰ－１結合ペプチド。
(項目２)
（ａ）の前記アミノ酸配列が、ＬＳＡＬＴＰＳＰＳＷＬＫＹＫＡＬ（配列番号１）である、項目１に記載の単離されたＤＰＥＰ－１結合ペプチド。
(項目３)
配列番号２、配列番号３および配列番号４からなる群から選択される、項目１に記載の単離されたＤＰＥＰ－１結合ペプチド。
(項目４)
ＰＥＧ化、アセチル化、グリコシル化、ビオチン化、プレニル化または環化によって改変されている、項目１に記載の単離されたＤＰＥＰ－１結合ペプチド。
(項目５)
Ｄ－アミノ酸、改変されたアミノ酸、アミノ酸アナログまたはそれらの組合せからなる群から選択される１つまたは複数のアミノ酸を含む、項目１に記載の単離されたＤＰＥＰ－１結合ペプチド。
(項目６)
改変されたアミノ酸が、メチル化、アミド化、アセチル化、および／または他の化学基による置換からなる群から選択される改変を含む、項目１に記載の単離されたＤＰＥＰ－１結合ペプチド。
(項目７)
項目１に記載の単離されたＤＰＥＰ－１結合ペプチドおよび少なくとも１つの医薬担体を含む医薬組成物。
(項目８)
必要なヒト対象において障害を処置または予防する方法であって、有効量の項目１に記載の単離されたＤＰＥＰ－１結合ペプチドを前記対象に投与するステップを含む、方法。
(項目９)
前記障害が、急性腎臓傷害、敗血症および腫瘍転移からなる群から選択される、項目８に記載の方法。
(項目１０)
前記障害が、炎症および虚血－再灌流傷害からなる群から選択される、項目８に記載の方法。
(項目１１)
前記虚血－再灌流傷害が、移植のためのドナー臓器を摘出することと関連する、項目１０に記載の方法。
(項目１２)
配列番号５、配列番号６、配列番号７および配列番号８から選択される配列を含む単離されたペプチド。
(項目１３)
前記配列が、配列番号５または＾から選択され、前記ペプチドが、ＤＰＥＰ－１に結合する、項目１２に記載の単離されたペプチド。
(項目１４)
前記配列が、配列番号７または配列番号８から選択され、前記ペプチドが、ＤＰＥＰ－１への結合を阻害する、項目１２に記載の単離されたペプチド。
(項目１５)
Ｎ末端に、少なくとも１、２、３、４または５個のアミノ酸残基をさらに含む、項目１２に記載の単離されたペプチド。
(項目１６)
Ｄ－アミノ酸、改変されたアミノ酸、アミノ酸アナログまたはそれらの組合せからなる群から選択される１つまたは複数のアミノ酸を含む、項目１２に記載の単離されたペプチド。
(項目１７)
改変されたアミノ酸が、メチル化、アミド化、アセチル化からなる群から選択される改変を含む、項目１５に記載の単離されたペプチド。
(項目１８)
項目１２に記載の単離されたペプチドおよび薬学的に許容される担体を含む医薬組成物。
(項目１９)
必要な対象において疾患または障害を処置する方法であって、有効量の項目１２に記載の単離されたペプチドを前記対象に投与するステップを含む、方法。
(項目２０)
前記疾患または障害が、急性腎臓傷害、敗血症および腫瘍転移からなる群から選択される、項目１９に記載の方法。
(項目２１)
前記障害が、炎症および虚血－再灌流傷害からなる群から選択される、項目１９に記載の方法。
(項目２２)
前記虚血－再灌流傷害が、移植のためのドナー臓器を摘出することと関連する、項目２１に記載の方法。
It will be appreciated how various changes and modifications may be made without departing from the invention.
The present invention provides, for example, the following items.
(Item 1)
An isolated DPEP-1 binding peptide comprising (a) an amino acid sequence comprising LSALT and (b) at least one additional glycine residue at the N-terminus.
(Item 2)
The isolated DPEP-1-binding peptide of item 1, wherein said amino acid sequence of (a) is LSALTPSPSWLKYKAL (SEQ ID NO: 1).
(Item 3)
The isolated DPEP-1-binding peptide of item 1, selected from the group consisting of SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4.
(Item 4)
The isolated DPEP-1-binding peptide of item 1, which is modified by pegylation, acetylation, glycosylation, biotinylation, prenylation or cyclization.
(Item 5)
The isolated DPEP-1-binding peptide of item 1, comprising one or more amino acids selected from the group consisting of D-amino acids, modified amino acids, amino acid analogs or combinations thereof.
(Item 6)
The isolated DPEP-1-binding peptide of item 1, wherein the modified amino acid comprises a modification selected from the group consisting of methylation, amidation, acetylation, and/or substitution with other chemical groups.
(Item 7)
A pharmaceutical composition comprising the isolated DPEP-1-binding peptide of item 1 and at least one pharmaceutical carrier.
(Item 8)
A method of treating or preventing a disorder in a human subject in need thereof, comprising administering to said subject an effective amount of the isolated DPEP-1-binding peptide of item 1.
(Item 9)
9. The method of item 8, wherein said disorder is selected from the group consisting of acute kidney injury, sepsis and tumor metastasis.
(Item 10)
9. The method of item 8, wherein said injury is selected from the group consisting of inflammation and ischemia-reperfusion injury.
(Item 11)
11. The method of item 10, wherein said ischemia-reperfusion injury is associated with removing a donor organ for transplantation.
(Item 12)
An isolated peptide comprising a sequence selected from SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8.
(Item 13)
13. The isolated peptide of item 12, wherein said sequence is selected from SEQ ID NO:5 or ^ and said peptide binds to DPEP-1.
(Item 14)
13. The isolated peptide of item 12, wherein said sequence is selected from SEQ ID NO:7 or SEQ ID NO:8 and said peptide inhibits binding to DPEP-1.
(Item 15)
13. The isolated peptide of item 12, further comprising at least 1, 2, 3, 4 or 5 amino acid residues at the N-terminus.
(Item 16)
13. The isolated peptide of item 12, comprising one or more amino acids selected from the group consisting of D-amino acids, modified amino acids, amino acid analogs or combinations thereof.
(Item 17)
16. The isolated peptide of item 15, wherein the modified amino acid comprises a modification selected from the group consisting of methylation, amidation, acetylation.
(Item 18)
A pharmaceutical composition comprising the isolated peptide of item 12 and a pharmaceutically acceptable carrier.
(Item 19)
13. A method of treating a disease or disorder in a subject in need thereof, comprising administering to said subject an effective amount of the isolated peptide of item 12.
(Item 20)
20. The method of item 19, wherein said disease or disorder is selected from the group consisting of acute kidney injury, sepsis and tumor metastasis.
(Item 21)
20. The method of item 19, wherein said injury is selected from the group consisting of inflammation and ischemia-reperfusion injury.
(Item 22)
22. The method of item 21, wherein said ischemia-reperfusion injury is associated with removing a donor organ for transplantation.
Claims (22)
22. The composition of claim 21, wherein said ischemia-reperfusion injury is associated with removing a donor organ for transplantation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024007364A JP2024028553A (en) | 2018-11-30 | 2024-01-22 | Dpep-1 binding agents and methods of use |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862773733P | 2018-11-30 | 2018-11-30 | |
| US62/773,733 | 2018-11-30 | ||
| PCT/IB2019/001289 WO2020109864A1 (en) | 2018-11-30 | 2019-12-02 | Dpep-1 binding agents and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024007364A Division JP2024028553A (en) | 2018-11-30 | 2024-01-22 | Dpep-1 binding agents and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022509258A JP2022509258A (en) | 2022-01-20 |
| JPWO2020109864A5 true JPWO2020109864A5 (en) | 2022-10-05 |
Family
ID=70853301
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021530885A Pending JP2022509258A (en) | 2018-11-30 | 2019-12-02 | DPEP-1 Binder and Method of Use |
| JP2024007364A Pending JP2024028553A (en) | 2018-11-30 | 2024-01-22 | Dpep-1 binding agents and methods of use |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024007364A Pending JP2024028553A (en) | 2018-11-30 | 2024-01-22 | Dpep-1 binding agents and methods of use |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11286278B2 (en) |
| EP (1) | EP3887390A4 (en) |
| JP (2) | JP2022509258A (en) |
| AU (1) | AU2019386379A1 (en) |
| CA (1) | CA3121300A1 (en) |
| IL (1) | IL283231A (en) |
| WO (1) | WO2020109864A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL307413A (en) * | 2021-04-08 | 2023-12-01 | Nat Res Council Canada | Dpep-1 binding agents and methods of use |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7223558B2 (en) * | 2001-07-11 | 2007-05-29 | Bristol-Myers Squibb Company | Polynucleotides encoding three novel human cell surface proteins with leucine rich repeats and immunologobulin folds, BGS2, 3, and 4 and variants thereof |
| US8258256B2 (en) * | 2006-01-05 | 2012-09-04 | The Johns Hopkins University | Compositions and methods for the treatment of cancer |
| WO2011131747A1 (en) * | 2010-04-20 | 2011-10-27 | Addex Pharma Sa | Chimeric polypeptides useful in proximal and dynamic high-throughput screening methods |
| US20120207742A1 (en) * | 2011-02-14 | 2012-08-16 | Allergan, Inc. | Treatments Using PSMA Ligand Endopeptidases |
| WO2015120536A1 (en) * | 2014-02-13 | 2015-08-20 | Arch Cancer Therapeutics, Inc. | Peptides that block leukocyte recruitment and methods of use |
| IL257458B2 (en) * | 2015-08-11 | 2024-01-01 | Arch Biopartners Inc | Dpep-1 binding compositions and methods of use |
| US11219646B2 (en) * | 2016-09-30 | 2022-01-11 | Baylor College Of Medicine | Chimeric antigen receptor therapy with reduced cytotoxicity for viral disease |
| EP3519436A4 (en) * | 2016-09-30 | 2020-09-09 | Baylor College of Medicine | Antibody based gene therapy with tissue-directed expression |
-
2019
- 2019-12-02 WO PCT/IB2019/001289 patent/WO2020109864A1/en unknown
- 2019-12-02 CA CA3121300A patent/CA3121300A1/en active Pending
- 2019-12-02 AU AU2019386379A patent/AU2019386379A1/en active Pending
- 2019-12-02 JP JP2021530885A patent/JP2022509258A/en active Pending
- 2019-12-02 EP EP19891278.4A patent/EP3887390A4/en active Pending
- 2019-12-02 US US16/700,901 patent/US11286278B2/en active Active
-
2021
- 2021-05-18 IL IL283231A patent/IL283231A/en unknown
-
2022
- 2022-02-14 US US17/670,998 patent/US20220251140A1/en active Pending
-
2024
- 2024-01-22 JP JP2024007364A patent/JP2024028553A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2007272272B2 (en) | Antimicrobial peptides | |
| JP2006149365A5 (en) | ||
| JP3147904B2 (en) | Broad spectrum antimicrobial compounds and methods of use | |
| US9907838B2 (en) | Composition and methods for treating ischemic damage | |
| JP4006021B2 (en) | Methods for enhancing the biological activity of chemokines | |
| JP2018171063A5 (en) | ||
| JP2011529084A5 (en) | ||
| EP1340767B9 (en) | Polypeptide useful as biomaterial and process for producing the same | |
| Ryge et al. | New indolicidin analogues with potent antibacterial activity | |
| Lee | Development of short antimicrobial peptides derived from host defense peptides or by combinatorial libraries | |
| ATE278708T1 (en) | CONOTOXIN PEPTIDE PVIIA | |
| JP7213811B2 (en) | Novel staple peptides and uses thereof | |
| JP2020526497A5 (en) | ||
| Himeshima et al. | Amino acid sequence of a lectin from the sea cucumber, Stichopus japonicus, and its structural relationship to the C-type animal lectin family | |
| US5585353A (en) | Antibiotic peptides containing D-amino acids | |
| Ryge et al. | Novel lysine‐peptoid hybrids with antibacterial properties | |
| JPH06504050A (en) | Modified hexa- and hepta-peptide anaphylatoxin receptor ligands | |
| DE69840024D1 (en) | Antimicrobial peptides derived from ubiquicidin | |
| Hojo | A strategy for the synthesis of hydrophobic proteins and glycoproteins | |
| JPH08504210A (en) | Treatment of septic shock using conjugated bioactive peptides | |
| JPWO2020109864A5 (en) | ||
| Bionda et al. | Solid‐phase synthesis of fusaricidin/li‐f class of cyclic lipopeptides: Guanidinylation of resin‐bound peptidyl amines | |
| EP3392263A1 (en) | Polypeptide compound, preparation method therefor and use thereof | |
| WO2013141750A1 (en) | Synthetic peptides wtih a non-narcotic type of analgesic effect | |
| Hilchie et al. | The application of cationic antimicrobial peptides in cancer treatment: laboratory investigations and clinical potential |